Narcolepsy 2 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Orphanet: ⁵⁸ A rare neurologic disease characterized by excessive daytime sleepiness associated with uncontrollable sleep urges and sometimes sleep paralysis, and hypnagogic/hypnopompic hallucinations.

MalaCards based summary: Narcolepsy 2, also known as narcolepsy 2, susceptibility to, is related to hypersomnia and idiopathic hypersomnia. An important gene associated with Narcolepsy 2 is NRCLP2 (Narcolepsy, HLA-Associated), and among its related pathways/superpathways are Immune response Function of MEF2 in T lymphocytes and Immune response Antigen presentation by MHC class II. The drugs Flumazenil and Dextroamphetamine have been mentioned in the context of this disorder. Affiliated tissues include eye, temporal lobe and amygdala, and related phenotypes are hallucinations and insomnia

More information from OMIM: 605841 PS161400

Sources

Related Diseases for Narcolepsy 2

Diseases in the Narcolepsy family:

Narcolepsy 1	Narcolepsy 2
Narcolepsy 3	Narcolepsy 4
Narcolepsy 5	Narcolepsy 6
Narcolepsy 7

Diseases related to Narcolepsy 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)

#	Related Disease	Score	Top Affiliating Genes
1	hypersomnia	30.2	HLA-DQB1 HCRT
2	idiopathic hypersomnia	30.2	HLA-DQB1 HCRT
3	sleep disorder	30.1	HLA-DQB1 HCRT
4	narcolepsy 1	29.4	ZNF365 HLA-DRB1 HLA-DQB1 HCRT
5	narcolepsy	28.3	ZNF365 NRCLP2 HLA-DRB1 HLA-DQB1 HCRT
6	syncope	10.1
7	apnea, obstructive sleep	10.1
8	recurrent hypersomnia	10.0	HLA-DQB1 HCRT
9	kleine-levin hibernation syndrome	10.0	HLA-DQB1 HCRT
10	periodic limb movement disorder	9.9	HLA-DQB1 HCRT
11	glioma susceptibility 1	9.9
12	delayed sleep phase disorder	9.9
13	sleep apnea	9.9
14	autoimmune encephalitis	9.9
15	glioma	9.9
16	oto-palatal-digital syndrome	9.9
17	postural tachycardia syndrome	9.9
18	glial tumor	9.9
19	pediatric multiple sclerosis	9.8	HLA-DRB1 HLA-DQB1
20	chronic beryllium disease	9.8	HLA-DRB1 HLA-DQB1
21	osteonecrosis of the jaw	9.8	HLA-DRB1 HLA-DQB1
22	persian gulf syndrome	9.8	HLA-DRB1 HLA-DQB1
23	podoconiosis	9.8	HLA-DRB1 HLA-DQB1
24	focal epithelial hyperplasia	9.8	HLA-DRB1 HLA-DQB1
25	pityriasis rosea	9.8	HLA-DRB1 HLA-DQB1
26	trachoma	9.8	HLA-DRB1 HLA-DQB1
27	cytomegalovirus retinitis	9.8	HLA-DRB1 HLA-DQB1
28	panuveitis	9.8	HLA-DRB1 HLA-DQB1
29	dermatitis herpetiformis	9.8	HLA-DRB1 HLA-DQB1
30	rheumatic fever	9.8	HLA-DRB1 HLA-DQB1
31	echinococcosis	9.8	HLA-DRB1 HLA-DQB1
32	chronic urticaria	9.8	HLA-DRB1 HLA-DQB1
33	japanese encephalitis	9.8	HLA-DRB1 HLA-DQB1
34	rheumatic heart disease	9.8	HLA-DRB1 HLA-DQB1
35	typhoid fever	9.8	HLA-DRB1 HLA-DQB1
36	severe cutaneous adverse reaction	9.8	HLA-DRB1 HLA-DQB1
37	silicosis	9.8	HLA-DRB1 HLA-DQB1
38	optic neuritis	9.8	HLA-DRB1 HLA-DQB1
39	calcinosis	9.8	HLA-DRB1 HLA-DQB1
40	lyme disease	9.8	HLA-DRB1 HLA-DQB1
41	pneumoconiosis	9.8	HLA-DRB1 HLA-DQB1
42	autoimmune disease of endocrine system	9.7	HLA-DRB1 HLA-DQB1
43	thyroiditis	9.7	HLA-DRB1 HLA-DQB1
44	mumps	9.7	HLA-DRB1 HLA-DQB1
45	rubella	9.7	HLA-DRB1 HLA-DQB1
46	visceral leishmaniasis	9.7	HLA-DRB1 HLA-DQB1
47	autoimmune disease of gastrointestinal tract	9.7	HLA-DRB1 HLA-DQB1
48	juvenile rheumatoid arthritis	9.7	HLA-DRB1 HLA-DQB1
49	pulmonary tuberculosis	9.7	HLA-DRB1 HLA-DQB1
50	alopecia areata	9.7	HLA-DRB1 HLA-DQB1

Graphical network of the top 20 diseases related to Narcolepsy 2:

Sources

Symptoms & Phenotypes for Narcolepsy 2

Human phenotypes related to Narcolepsy 2:

⁵⁸ ³⁰

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	hallucinations ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000738
2	insomnia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0100785
3	excessive daytime somnolence ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001262
4	sleep disturbance ⁵⁸		Very frequent (99-80%)
5	behavioral abnormality ⁵⁸		Occasional (29-5%)

Clinical features from OMIM®:

605841 (Updated 08-Dec-2022)

Sources

Drugs & Therapeutics for Narcolepsy 2

Drugs for Narcolepsy 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Flumazenil

Approved

Phase 1, Phase 2

78755-81-4

3373

2

Dextroamphetamine

Approved, Illicit, Investigational

Phase 2

51-64-9, 300-62-9

5826 3007

Synonyms:

(±)-amphetamine|Amphetamine Sulfate®|DL-amphetamine

(+)-(S)-Amphetamine

(+)-alpha-Methylphenethylamine

(+)-alpha-Methylphenylethylamine

(+-)-alpha-Methylphenylethylamine

(+)-a-Methylphenethylamine

(+)-a-Methylphenylethylamine

(+)-Amphetamine

(+)-phenaminum

(+)-Α-methylphenethylamine

(+)-Α-methylphenylethylamine

(+/-)-benzedrine

(+/-)-beta-phenylisopropylamine

(+/-)-desoxynorephedrine

(2S)-(+)-Amphetamine

(2S)-1-phenylpropan-2-amine

(AlphaS)-alpha-methylbenzeneethanamine

(AlphaS)-a-methylbenzeneethanamine

(AlphaS)-α-methylbenzeneethanamine

(S)-(+)-Amphetamine

(S)-(+)-beta-Phenylisopropylamine

(S)-(+)-b-Phenylisopropylamine

(S)-(+)-Β-phenylisopropylamine

(S)-1-Phenyl-2-aminopropane

(S)-1-Phenyl-2-propanamine

(S)-1-Phenyl-2-propylamine

(S)-alpha-Methylbenzeneethanamine

(s)-alpha-methylphenethylamine

(s)-alpha-phenylethylamine

(S)-a-Methylbenzeneethanamine

(S)-Amphetamine

(S)-Α-methylbenzeneethanamine

(αS)-α-methylbenzeneethanamine

[1-(3-Methoxyphenyl)-2-propyl]amine

1-Methyl-2-phenylethylamine

1-Phenyl-2-aminopropane

3-Methoxy-a-methylbenzeneethanamine

3-Methoxyamphetamine

3-Methoxyphenylisopropylamine

Actedron

Adipan

Adzenys

ADZENYS ER

ADZENYS XR-ODT

Allodene

alpha-Methylbenzeneethaneamine

Amfetamin

Amfetamina

Amfetamine

Amfetaminum

Amphetamine

AMPHETAMINE RESIN COMPLEX

Amphetamine sulfate

Amphetamine sulfate (2:1)

Amsustain

Anorexide

Anorexine

Benzebar

Benzedrine

Benzolone

beta-Aminopropylbenzene

beta-Phenylisopropylamin

beta-Phenyl-isopropylamine

Celltech brand OF dextroamphetamine sulfate

Centramina

Curban

D Amphetamine

D Amphetamine sulfate

D-(+)-amphetamine

D-(s)-amphetamine

D-1-Phenyl-2-aminopropan

d-1-Phenyl-2-aminopropan [German]

D-1-Phenyl-2-aminopropane

D-2-Amino-1-phenylpropane

D-alpha-methylphenethylamine

D-am

D-Amphetamine

D-Amphetamine sulfate

Dephadren

Desamfetamina

Desoxyn

Desoxynorephedrin

Desoxynorephedrine

Dexacaps

Dexadrine

Dexamfetamina

Dexamfetamina [inn-spanish]

Dexamfetamine

Dexamfetaminum

Dexamfetaminum [inn-latin]

DEXAMPEX

Dexamphetamine

Dexamphetaminum [inn-latin]

Dexanfetamina

Dexanfetamina [inn-spanish]

Dexedrine

Dexedrine Spansule

Dexidrine

Dextro amphetamine

Dextro amphetamine sulfate

Dextroamphetamine

Dextro-amphetamine

DEXTROAMPHETAMINE RESIN COMPLEX

Dextroamphetamine sulfate

Dextro-amphetamine sulfate

DextroStat

DL-1-Phenyl-2-aminopropane

DL-alpha-Methylphenethylamine

DL-Amphetamine

DL-Benzedrine

Dyanavel

DYANAVEL XR

Elastonon

Fenamin

Fenamine

Fenylo-izopropylaminyl

FERNDEX

Finam

GlaxoSmithKline brand OF dextroamphetamine sulfate

Isoamycin

Isoamyne

Isomyn

L Amphetamine

L-Amphetamine

Levo amphetamine

Levoamphetamine

Levo-amphetamine

Mallinckrodt brand OF dextroamphetamine sulfate

Mecodrin

Methampex

Methamphetamine HCL

Miquel brand OF amfetamine sulfate

m-Methoxy-a-methylphenethylamine

m-Methoxyamphetamine

Mydrial

Norephedrane

Novydrine

NSC-27159

NSC-73713

Oktedrin

Ortedrine

Oxydess

Paredrine

Pasadena brand OF dextroamphetamine

Percomon

Phenamine

Phenedrine

Phenopromin

Phenylisopropylamine

Profamina

Propisamine

Psychedrine

rac-(2R)-1-phenylpropan-2-amine

rac-amphetamine

Raphetamine

Rhinalator

S(+)-amphetamine

Shire brand OF dextroamphetamine sulfate

Simpatedrin

Simpatina

Sulfate, amphetamine

Sulfate, dextroamphetamine

Sympamin

Sympamine

Sympatedrine

Thyramine

Vortech brand OF dextroamphetamine sulfate

Weckamine

α-methylbenzeneethaneamine

α-methylphenethylamine

β-aminopropylbenzene

β-phenylisopropylamine

3

Modafinil

Approved, Investigational

Phase 2

68693-11-8

4236

4

Clarithromycin

Approved

Phase 2

81103-11-9

84029

5

Dopamine

Approved

Phase 2

62-31-7, 51-61-6

681

6

Mazindol

Approved, Investigational

Phase 2

22232-71-9

4020

7

Antidotes

Phase 1, Phase 2

8

GABA Modulators

Phase 1, Phase 2

9

Protective Agents

Phase 1, Phase 2

10

Adderall

Phase 2

11

Sympathomimetics

Phase 2

12

Antibiotics, Antitubercular

Phase 2

13

Anti-Bacterial Agents

Phase 2

14

Anti-Infective Agents

Phase 2

15

Cytochrome P-450 Enzyme Inhibitors

Phase 2

16

Cytochrome P-450 CYP3A Inhibitors

Phase 2

17

Central Nervous System Stimulants

Phase 2

18

Neurotransmitter Agents

Phase 2

19

Adrenergic Agents

Phase 2

20

Dopamine Uptake Inhibitors

Phase 2

21

Dopamine Agents

Phase 2

Interventional clinical trials:

(show all 11)

#	Name	Status	NCT ID	Phase	Drugs
1	Double Blind, Multicentre, Randomized, Placebo-controlled Trial to Evaluate Safety and Efficacy of Pitolisant in Children From 6 to Less Than 18 Years With Narcolepsy With/Without Cataplexy, Followed by a Prolonged Open-label Period	Active, not recruiting	NCT02611687	Phase 3	pitolisant;Placebo
2	A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2	Completed	NCT02512588	Phase 2	BTD-001;Placebo
3	A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors	Completed	NCT01183312	Phase 1, Phase 2	Flumazenil
4	Informing Treatment Decisions in the Central Disorders of Hypersomnolence: A Pragmatic Clinical Trial of Modafinil Versus Amphetamines	Recruiting	NCT03772314	Phase 2	Modafinil;Amphetamine-Dextroamphetamine
5	Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes	Recruiting	NCT04026958	Phase 2	Clarithromycin;Placebo
6	A 6-Month Multicenter, Open-Labelled Extension of the Clinical Trial NLS-1021 in Narcoleptic Patients With and Without Cataplexy	Enrolling by invitation	NCT05055024	Phase 2	Mazindol
7	A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)	Terminated	NCT04096560	Phase 2	TAK-994;Placebo
8	Mind-Body Approach to Improve Health-Related Quality of Life for People With Narcolepsy	Completed	NCT04306952
9	Coordination of Rare Diseases at Sanford	Recruiting	NCT01793168
10	An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy	No longer available	NCT03433131		Pitolisant
11	'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'	Suspended	NCT04419792

Search NIH Clinical Center for Narcolepsy 2

Sources

Genetic Tests for Narcolepsy 2

Genetic tests related to Narcolepsy 2:

#	Genetic test	Affiliating Genes
1	Narcolepsy 2, Susceptibility to ²⁸

Sources

Anatomical Context for Narcolepsy 2

Organs/tissues related to Narcolepsy 2:

MalaCards : Eye, Temporal Lobe, Amygdala, Thalamus, Brain, Pituitary, Heart

Sources

Publications for Narcolepsy 2

Articles related to Narcolepsy 2:

(show top 50) (show all 185)

#	Title	Authors	PMID	Year
1	Linkage of human narcolepsy with HLA association to chromosome 4p13-q21. ⁵⁷	Nakayama J...Arinami T	10777671	2000
2	Differential characteristics of repeated polysomnography and multiple sleep latency test parameters in narcolepsy type 1 and type 2 patients: a longitudinal retrospective study. ⁶²	Um YH...Hong SC	34820763	2022
3	Differentiation of central disorders of hypersomnolence with manual and artificial-intelligence-derived polysomnographic measures. ⁶²	Cesari M...Heidbreder A	36455881	2022
4	Central Disorders of Hypersomnolence: Association with Fatigue, Depression and Sleep Inertia Prevailing in Women. ⁶²	Nevsimalova S...Sonka K	36358417	2022
5	Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort. ⁶²	Mutti C...Plazzi G	35750949	2022
6	Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients. ⁶²	Evans R...Mignot E	35994639	2022
7	Narcolepsy. ⁶²	Barateau L...Dauvilliers Y	35624073	2022
8	18F-FDG Brain PET Findings in Narcolepsy Type 2. ⁶²	Varughese RT...Franceschi AM	35797634	2022
9	The association between narcolepsy during pregnancy and maternal-fetal risk factors/outcomes. ⁶²	Wilson A...Salihu HM	36158716	2022
10	The REM-sleep-related characteristics of narcolepsy: a nation-wide multicenter study in Turkey, the REMCON study. ⁶²	Akyildiz UO...Senel GB	35447401	2022
11	Data-Driven Phenotyping of Central Disorders of Hypersomnolence With Unsupervised Clustering. ⁶²	Gool JK...Lammers GJ	35437263	2022
12	Comorbid parasomnias in narcolepsy and idiopathic hypersomnia: more REM than NREM parasomnias. ⁶²	Leu-Semenescu S...Arnulf I	34984974	2022
13	The Psychomotor Vigilance Test as a measure of alertness and sleep inertia in people with central disorders of hypersomnolence. ⁶²	Trotti LM...Bliwise DL	35040431	2022
14	Development and Validation of the Pediatric Hypersomnolence Survey. ⁶²	Maski K...Sideridis G	35314496	2022
15	The diagnostic value of sleep and vigilance tests in central disorders of hypersomnolence. ⁶²	Mathis J...Schreier DR	35038747	2022
16	Sleeping through a pandemic: impact of COVID-19-related restrictions on narcolepsy and idiopathic hypersomnia. ⁶²	Nigam M...Arnulf I	34314345	2022
17	The Impact of Sleep Pattern in School/Work Performance During the COVID-19 Home Quarantine in Patients With Narcolepsy. ⁶²	Zhao M...Zhang X	35847213	2022
18	Idiopathic Hypersomnia: Historical Account, Critical Review of Current Tests and Criteria, Diagnostic Evaluation in the Absence of Biological Markers and Robust Electrophysiological Diagnostic Criteria. ⁶²	Billiard M...Sonka K	35450222	2022
19	The Swiss Primary Hypersomnolence and Narcolepsy Cohort study (SPHYNCS): Study protocol for a prospective, multicentre cohort observational study. ⁶²	Dietmann A...Bassetti CLA	33813771	2021
20	Cognitive dysfunction in central disorders of hypersomnolence: A systematic review. ⁶²	Filardi M...Plazzi G	34166991	2021
21	Narcolepsy: the impact of aging, hypocretin deficiency, and years of formal education in olfactory function and abdominal obesity. ⁶²	Truzzi GM...Coelho FM	34495122	2021
22	Changes in physiological network connectivity of body system in narcolepsy during REM sleep. ⁶²	Son DY...Park KS	34399195	2021
23	Polysomnographic nighttime features of narcolepsy: A systematic review and meta-analysis. ⁶²	Zhang Y...Tang X	33934047	2021
24	Stability of nocturnal wake and sleep stages defines central nervous system disorders of hypersomnolence. ⁶²	Maski KP...Diniz Behn C	33512510	2021
25	Cerebrospinal fluid monoamine levels in central disorders of hypersomnolence. ⁶²	Barateau L...Dauvilliers Y	33476396	2021
26	Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study. ⁶²	Dubessy AL...Stankoff B	33931534	2021
27	Narcolepsy type 2: A rare, yet existing entity. ⁶²	Baumann-Vogel H...Baumann CR	32989797	2021
28	Cortical arousal frequency is increased in narcolepsy type 1. ⁶²	Brink-Kjaer A...Jennum P	33249455	2021
29	Nocturnal Rapid Eye Movement Sleep Without Atonia can Be a Diagnostic Parameter in Differentiating Narcolepsy Type 1 From Type 2. ⁶²	Yon MI...Tezer FI	32141986	2021
30	Actigraphy measurement of physical activity and energy expenditure in narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia: A Sensewear Armband study. ⁶²	Bornstein A...Wasling P	32281246	2021
31	Type 1 narcolepsy without cataplexy and treatment progress: a case report. ⁶²	Huang R...Chen X	33849131	2021
32	[Narcolepsy in adults: Definition, etiology and treatment]. ⁶²	Malter M...Kallweit U	33339064	2021
33	Secondary Narcolepsy in Children. ⁶²	Madan R...Kotagal S	32933368	2021
34	A practical guide to the pharmacological and behavioral therapy of Narcolepsy. ⁶²	Franceschini C...Plazzi G	33886090	2021
35	On-the-road driving performance of patients with central disorders of hypersomnolence. ⁶²	van der Sluiszen NNJJM...Vermeeren A	33543997	2021
36	Safety of Influenza A H1N1pdm09 Vaccines: An Overview of Systematic Reviews. ⁶²	Juvet LK...Trogstad L	34777351	2021
37	Coexistence of Hereditary Spastic Paraplegia Type 4 and Narcolepsy: A Case Report. ⁶²	Nagai T...Ozawa T	33708099	2021
38	Disease symptomatology and response to treatment in people with idiopathic hypersomnia: initial data from the Hypersomnia Foundation registry. ⁶²	Trotti LM...Bliwise DL	32950878	2020
39	Defining disrupted nighttime sleep and assessing its diagnostic utility for pediatric narcolepsy type 1. ⁶²	Maski K...Plazzi G	32253429	2020
40	Central Disorders of Hypersomnolence. ⁶²	Trotti LM	32756227	2020
41	Sleep-Wake Disorders in Childhood. ⁶²	Licis A	32756235	2020
42	Diagnosis of central disorders of hypersomnolence: A reappraisal by European experts. ⁶²	Lammers GJ...Dauvilliers Y	32311642	2020
43	To split or to lump? Classifying the central disorders of hypersomnolence. ⁶²	Fronczek R...Trotti LM	32193539	2020
44	Case report: narcolepsy type 2 due to temporal lobe glioma. ⁶²	Liao Y...Huang F	32664104	2020
45	Isolated Central Hypothyroidism in an Adolescent With Narcolepsy. ⁶²	Alhajri S...Perez-Colon S	32656014	2020
46	Pharmacologic Management of Excessive Daytime Sleepiness. ⁶²	Takenoshita S...Nishino S	32386693	2020
47	Narcolepsy treatment: pharmacological and behavioral strategies in adults and children. ⁶²	Franceschini C...Plazzi G	31290083	2020
48	Comorbid psychiatric disorders among patients with narcolepsy. ⁶²	Alasim H...BaHammam AS	31280401	2020
49	Health-related quality of life in patients with narcolepsy types 1 and 2 from a Sleep Center in Brazil. ⁶²	Cremaschi RC...Coelho FM	32627808	2020
50	Utility of the sleep stage sequence preceding sleep onset REM periods for the diagnosis of narcolepsy: a study in a Japanese cohort. ⁶²	Kawai R...Kitajima T	31999982	2020

Sources

Genes for Narcolepsy 2

Genes related to Narcolepsy 2 (5 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NRCLP2	Narcolepsy, HLA-Associated	Genetic Locus	50	Genetic linkage ⁵⁷
2	HCRT	Hypocretin Neuropeptide Precursor	Protein Coding	25	Candidate gene tested ⁵⁸	10973318 23643651
3	HLA-DQB1	Major Histocompatibility Complex, Class II, DQ Beta 1	Protein Coding	25	Susceptibility factor ⁵⁸	18706091 21345702
4	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	25	Susceptibility factor ⁵⁸	18706091 19410508
5	ZNF365	Zinc Finger Protein 365	Protein Coding	25	Susceptibility factor ⁵⁸	24204295

Sources

Variations for Narcolepsy 2

Sources

Expression for Narcolepsy 2

Search GEO for disease gene expression data for Narcolepsy 2.

Sources

Pathways for Narcolepsy 2

Pathways related to Narcolepsy 2 according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Immune response Function of MEF2 in T lymphocytes ²² Show member pathways Calcium Mediated T-Cell Apoptosis ⁶⁴ Development Role of HDAC and calcium/calmodulin-dependent kinase (CaMK) in control of skeletal myogenesis ²² SARS-CoV-2 targets host intracellular signalling and regulatory pathways ⁶⁶	11.72	HLA-DRB1 HLA-DQB1
2	Immune response Antigen presentation by MHC class II ²² Show member pathways G-protein signaling N-RAS regulation pathway ²² IL-22 Pathway ⁶⁴ Immune response IL-22 signaling pathway ²²	11.49	HLA-DRB1 HLA-DQB1
3	Ebola virus infection in host ⁷⁴	11.48	HLA-DRB1 HLA-DQB1
4	S-1P Stimulated Signaling ⁶⁴	11.42	HLA-DRB1 HLA-DQB1
5	Allograft rejection ⁷⁴	11.12	HLA-DRB1 HLA-DQB1
6	THC Differentiation Pathway ⁶⁴	10.92	HLA-DRB1 HLA-DQB1
7	Phosphorylation of CD3 and TCR zeta chains ⁶⁶ Show member pathways Generation of second messenger molecules ⁶⁶ PD-1 signaling ⁶⁶	10.85	HLA-DRB1 HLA-DQB1
8	CTL Mediated Apoptosis ⁶⁴	10.2	HLA-DRB1 HLA-DQB1

Sources

GO Terms for Narcolepsy 2

Cellular components related to Narcolepsy 2 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	endocytic vesicle membrane	GO:0030666	9.5	HLA-DRB1 HLA-DQB1
2	clathrin-coated endocytic vesicle membrane	GO:0030669	9.43	HLA-DRB1 HLA-DQB1
3	ER to Golgi transport vesicle membrane	GO:0012507	9.33	HLA-DRB1 HLA-DQB1
4	transport vesicle membrane	GO:0030658	9.13	HLA-DRB1 HLA-DQB1
5	MHC class II protein complex	GO:0042613	8.92	HLA-DRB1 HLA-DQB1

Biological processes related to Narcolepsy 2 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	humoral immune response	GO:0006959	9.58	HLA-DRB1 HLA-DQB1
2	positive regulation of T cell activation	GO:0050870	9.5	HLA-DRB1 HLA-DQB1
3	antigen processing and presentation of exogenous peptide antigen via MHC class II	GO:0019886	9.43	HLA-DRB1 HLA-DQB1
4	antigen processing and presentation	GO:0019882	9.37	HLA-DRB1 HLA-DQB1
5	peptide antigen assembly with MHC class II protein complex	GO:0002503	9.33	HLA-DRB1 HLA-DQB1
6	immunoglobulin production involved in immunoglobulin-mediated immune response	GO:0002381	8.96	HLA-DRB1 HLA-DQB1
7	antigen processing and presentation of peptide or polysaccharide antigen via MHC class II	GO:0002504	8.62	HLA-DRB1 HLA-DQB1

Molecular functions related to Narcolepsy 2 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	peptide antigen binding	GO:0042605	9.33	HLA-DRB1 HLA-DQB1
2	MHC class II protein complex binding	GO:0023026	9.13	HLA-DRB1 HLA-DQB1
3	MHC class II receptor activity	GO:0032395	8.8	HLA-DRB1 HLA-DQB1

Sources

Sources for Narcolepsy 2

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

NRCLP2 MCID: NRC010 MIFTS: 41	Narcolepsy 2 (NRCLP2) Categories: Eye diseases, Genetic diseases, Mental diseases, Muscle diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Narcolepsy 2 (NRCLP2)

Aliases & Classifications for Narcolepsy 2

MalaCards integrated aliases for Narcolepsy 2:

Characteristics:

Prevelance:

Age Of Onset:

Classifications:

External Ids:

Summaries for Narcolepsy 2

Related Diseases for Narcolepsy 2

Diseases in the Narcolepsy family:

Diseases related to Narcolepsy 2 via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Narcolepsy 2:

Symptoms & Phenotypes for Narcolepsy 2

Human phenotypes related to Narcolepsy 2:

Clinical features from OMIM®:

Drugs & Therapeutics for Narcolepsy 2

Drugs for Narcolepsy 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Genetic Tests for Narcolepsy 2

Genetic tests related to Narcolepsy 2:

Anatomical Context for Narcolepsy 2

Organs/tissues related to Narcolepsy 2:

Publications for Narcolepsy 2

Articles related to Narcolepsy 2:

Genes for Narcolepsy 2

Genes related to Narcolepsy 2 (5 elite genes):

Variations for Narcolepsy 2

Expression for Narcolepsy 2

Pathways for Narcolepsy 2

Pathways related to Narcolepsy 2 according to GeneCards Suite gene sharing:

GO Terms for Narcolepsy 2

Cellular components related to Narcolepsy 2 according to GeneCards Suite gene sharing:

Biological processes related to Narcolepsy 2 according to GeneCards Suite gene sharing:

Molecular functions related to Narcolepsy 2 according to GeneCards Suite gene sharing:

Sources for Narcolepsy 2